Biochemical Engineering Special Interest Group
biological engineering professionals
27 April 2017

Synairgen insists lead drug has potential despite AZ pulling the plug

Shares in U.K. biotech Synairgen are in steep decline today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412. AZ revealed its decision as it reported first-quarter results this morning, leading to a run on Synairgen with the stock down almost 50% at the time of writing—and despite a statement from chief executive Richard Marsden saying that the program is still active. Source: Fierce Biotech 27/4/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).